secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2022-03-07T23:59:59+00:00
Accession:  0001193125-22-067928
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Director Jeffrey K. Tong to resign from Nurix board, effective at 2022 annual meeting
--------------------------------------------------------------------------------

- Jeffrey K. Tong, Ph.D., will resign as Class II director and from Audit and Compensation Committees.
- Resignation effective as of date of 2022 Annual Meeting of Stockholders.
- Resignation not due to any disagreement with the Company on operations, policies, or practices.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000119312522067928/0001193125-22-067928-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000119312522067928/d324477d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-067928

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer